Can-Fite BioPharma has filed a clinical trial application (CTA) with Health Canada for piclidenoson (CF101) as a treatment for rheumatoid arthritis (RA). Piclidenoson is an orally bioavailable drug with a favorable therapeutic index that is under development for the treatment of autoimmune inflammatory diseases like RA and psoriasis. It’s a new, first-in-class A3 adenosine receptor agonist (A3AR). […]

Rheumatoid arthritis (RA) patients taking Remicade (infliximab) can safely switch to CT-P13 (developed by Celltrion) — a much cheaper biosimilar of Remicade — according to a Norwegian study published in The Lancet. The study, “Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial,” was funded by […]

A large-scale genetic study, in combination with information from electronic health records (EHRs), identified new human leukocyte antigen (HLA) associations with several immune conditions, including rheumatoid arthritis and multiple sclerosis. The findings were reported in the study “Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants,” and published in the journal Science […]